DexCom, Inc. (NASDAQ: DXCM) has been under pressure over the past year as investors weigh near-term volatility against strong long-term demand for continuous glucose monitoring systems. The stock trades near $70/share, down about 6% over the past year, while growth in its G7 sensor and new international markets continues to drive optimism.
Recently, DexCom announced the rollout of its G7 system in new global markets and shared updates on its next-generation G8 sensor, which promises faster readings and wider accessibility. The company also continues expanding partnerships with major healthcare providers to improve reimbursement coverage and patient adoption. These developments reinforce DexCom’s position as a category leader driving innovation in diabetes technology.
This article explores where Wall Street analysts think DexCom could trade by 2027. We have compiled consensus price targets and valuation models to outline the stock’s potential path. These figures reflect current analyst expectations and are not TIKR’s own predictions.
Find out what a stock’s really worth in under 60 seconds with TIKR’s new Valuation Model (It’s free) >>>
Analyst Price Targets Suggest Meaningful Upside
DexCom trades around $70/share today. The average analyst price target sits near $98/share, suggesting about 40% upside over the next year. Forecasts show a fairly tight range among analysts:
- High estimate: ~$115/share
- Low estimate: ~$83/share
- Median target: ~$100/share
- Ratings: 20 Buys, 4 Outperforms, 4 Holds
It looks like analysts see meaningful room for gains, supported by DexCom’s growing G7 adoption and improving profitability.
For investors, that reflects confidence in the company’s ability to keep compounding through innovation and global market expansion.
Discover how much upside your favorite stocks could have using TIKR’s new Valuation Model (It’s free) >>>
DexCom: Growth Outlook and Valuation
DexCom’s fundamentals remain strong and improving:
- Revenue is projected to grow about 15% annually through 2027
- Operating margins are expected to reach 24%
- Shares trade near 30x forward earnings, supported by steady profit expansion
- Based on analysts’ average estimates, TIKR’s Guided Valuation Model using a 30x forward P/E suggests ~$104/share by 2027
- That implies roughly 47% total upside, or 19% annualized returns
These forecasts indicate DexCom can continue compounding earnings at a healthy pace as it scales its user base and improves efficiency.
For investors, the valuation looks reasonable for a company of this quality. Continued execution and innovation could support double-digit returns and reinforce DexCom’s leadership in continuous glucose monitoring.
See a stock’s true value in under 60 seconds (Free with TIKR) >>>
What’s Driving the Optimism?
DexCom’s growth story is built on innovation and reach. The G7 platform continues to gain traction globally, offering better comfort, accuracy, and app integration for users. The upcoming G8 sensor could strengthen that advantage and open new markets.
Margins are expanding as manufacturing becomes more efficient, while recurring revenue from sensor replacements supports predictable cash flow.
For investors, these strengths suggest DexCom is well positioned to sustain high growth and steady profitability over the next several years.
Bear Case: Valuation and Competitive Risk
DexCom’s premium valuation leaves little room for mistakes. Competition is heating up, with Abbott and other CGM players investing heavily in next-generation devices. Any pricing pressure or slower-than-expected adoption could weigh on results.
For investors, the key risk is that strong execution is already priced in. If adoption or reimbursement growth slows, the stock’s premium multiple could limit returns.
Outlook for 2027: What Could DexCom Be Worth?
Based on analysts’ average estimates, TIKR’s Guided Valuation Model suggests DexCom could trade near $104/share by 2027, representing about 47% total upside or roughly 19% annualized returns.
That outlook assumes continued global adoption, steady margin expansion, and successful product execution.
For investors, DexCom remains one of the highest-quality growth names in healthcare technology, combining innovation, recurring revenue, and long-term compounding potential.
Find out what your favorite stocks are really worth (Free with TIKR) >>>
AI Compounders With Massive Upside That Wall Street Is Overlooking
Everyone wants to cash in on AI. But while the crowd chases the obvious names benefiting from AI like NVIDIA, AMD, or Taiwan Semiconductor, the real opportunity may lie on the AI application layer where a handful of compounders are quietly embedding AI into products people already use every day.
TIKR just released a new free report on 5 undervalued compounders that analysts believe could deliver years of outperformance as AI adoption accelerates.
Inside the report, you’ll find:
- Businesses already turning AI into revenue and earnings growth
- Stocks trading below fair value despite strong analyst forecasts
- Unique picks most investors haven’t even considered
If you want to catch the next wave of AI winners, this report is a must-read.
Click here to sign up for TIKR and get your free copy of TIKR’s 5 AI Compounders report today.
